The purpose of this study is to evaluate the influence of non betablockers in gastrointestinal motility (transit time) in patients with liver cirrhosis.
There is some evidence that cirrhotic patients have increased gastrointestinal transit time, this issue may favor bacterial owergrowth, and consequently bacterial translocation. Translocation of bacterias and its products are linked to vascular and hemodynamics alterations that produce descompensation on the disease. There is evidence , in animal models , that the use of beta blockers favors the gastrointestinal movement; decompensated cirrhotics had significantly longer small bowel transit time as compared with compensated cirrhotics, there have described that this alteration is related to de cirrhosis severity as assessed by Child Pugh score. The purpose of this study is to evaluate the gastrointestinal transit time before and after treatment of non selective betablockers, we are going to evaluate the gastrointestinal time before and after of 4 weeks of non selectivebetablocker treatment, in decompensated cirrhotics. The gastrointestinal time is going to be evaluate by the ingestion of a device known as "smart pill", that allow ambulatory monitoring of gastrointestinal transit.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
10
the patient is going to receive a device called "smart pill" before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time
Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán
Mexico City, Mexico City, Mexico
RECRUITINGGastrointestinal transit time before and after treatment with no selective betablocker
gastrointestinal time evaluated by a device called Smart pill
Time frame: 4 weeks of maximum non betablocker dose
Evaluatiuon of genes of tight junctions proteins before and after treatment with no selective betablocker
gene expression of tight junctions proteins in duodenal and gastric epithelium
Time frame: 4 weeks of maximum non betablocker dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.